Grifols, S.A. and Talecris Biotherapeutics Holdings Corp. have signed a consent agreement with the U.S. Federal Trade Commission (FTC) outlining the conditions for Grifols’ acquisition of Talecris. Grifols has agreed to the sale of select assets and has entered into certain commercial, lease and manufacturing agreements with the Italian company Kedrion for as many as seven years.

Kedrion and Grifols will have a contract manufacturing agreement to fractionate and purify Kedrion’s plasma and to deliver IVIG and Albumin under Kedrion’s private label, and Factor VIII under the trade name Koate, for sale in the U.S.

Grifols will sell its Melville, N.Y. fractionation facility to Kedrion and Grifols will manage the facility for as long as four years under a lease agreement with Kedrion. Grifols will also sell Talecris’ U.S. FVIII business (Koate) and two Talecris plasma collection centers to Kedrion.

The consent agreement remains subject to approval by the FTC and until the acquisition is finalized, both companies remain independent and will conduct business as usual.